MedDataX Logo

Brain Biomarker on Inflammation Response

NCT ID: NCT03271814

Last Updated: 2023-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-01

Study Completion Date

2025-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a double-blinded, randomized, parallel controlled design, patients with schizophrenia spectrum disorder will be exposed to a single dose of lipopolysaccharide (LPS) (LPS-patient). Clinical symptoms, blood samples, and brain imaging will be assessed at baseline and after LPS. There will be two comparison groups. Comparison groups include an age- and sex-matched healthy control group also exposed to the same LPS (LPS-control), and an age- and sex-matched sample of patients with schizophrenia on placebo (Placebo-patient). As in Phase I studies, multiple interim analyses are expected so the current design may be modified, which will be communicated during annual reports (21CFR312.30).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Schizophrenia spectrum disorders are a major public health burden due to functional and cognitive impairment, psychosis and other symptoms, and high comorbidity. Unfortunately, current therapies have limited effectiveness in treating some of the symptoms and most of the cognitive deficits. Alternative biological models of the disease are needed for developing new and more effective treatment. Neuroinflammation has increasingly been implicated in the pathophysiology of schizophrenia. Patients with schizophrenia have signs of low-grade, chronic inflammation, including elevated blood levels of pro-inflammatory cytokines and other immune markers. Administration of LPS is the standard immune challenge to investigate the body's immune response in a wide range of disorders. Our goal is to use LPS to investigate whether schizophrenia patients have abnormal immune response to LPS and whether the abnormality is associated with specific brain imaging biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LPS-Patient

Schizophrenia patients who are randomized to receive LPS injection.

Group Type EXPERIMENTAL

LPS

Intervention Type BIOLOGICAL

0.6 by/kg LPS single dose iv

LPS-Healthy

Healthy controls who are randomized to receive LPS injection.

Group Type ACTIVE_COMPARATOR

LPS

Intervention Type BIOLOGICAL

0.6 by/kg LPS single dose iv

Placebo-Patient

Schizophrenia patients who are randomized to receive placebo injection.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Sterile Water

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LPS

0.6 by/kg LPS single dose iv

Intervention Type BIOLOGICAL

Placebo

Sterile Water

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-55
2. Patients must be on antipsychotic medication and clinically stable, defined as no hospitalization or major change in antipsychotic medication in the past 4 weeks
3. Patients must pass the ESC with score 10 or above
4. BMI 35 or less -

Exclusion Criteria

1. History of major medical illness including, but not limited to, history of heart attack, stroke, TIA (transient ischemic attack)
2. History of organic brain disorders that may affect neurophysiological measurements, including seizure disorder, brain tumor, head injury with evidence of significant cognitive deterioration
3. DSM diagnosis of substance use disorder within 6 months except nicotine and marijuana
4. Prior suicide attempt or frequent suicidal ideations, or current suicidal ideation assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
5. Women who have positive urine pregnancy tests; Women who plan to become pregnant, or are breastfeeding
6. Frequent (more than once) history of syncope (fainting) of unknown reason
7. Unable to undergo MRI scanning due to metallic devices or objects or claustrophobia
8. Presence of co-morbid inflammatory disorders such as rheumatoid arthritis
9. Presence of acute or chronic infection; have received flu or similar vaccine in the past 4 weeks
10. Current regular use of non-steroidal anti-inflammatory drugs or immune modifying drugs
11. Clinically significant abnormalities on screening laboratory tests
12. Blood pressure \<90/60 or \> 150/100, or pulse \<55 or \> 100 beats/minute, or temperature \> 99.5°F
13. 12-Lead ECG demonstrating QTcF \>450 msec or a QRS interval \>120 msec. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF values should be used to determine the subject's eligibility

\-
Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Maryland, Baltimore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

L. Elliot Hong

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

L E Hong, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Maryland, Baltimore

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HP-00076657

Identifier Type: -

Identifier Source: org_study_id